389 related articles for article (PubMed ID: 26026604)
1. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis.
Reiss WG; Devenport JN; Low JM; Wu G; Sasso EH
Rheumatol Int; 2016 Feb; 36(2):295-300. PubMed ID: 26026604
[TBL] [Abstract][Full Text] [Related]
2. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study.
Hirata S; Li W; Defranoux N; Cavet G; Bolce R; Yamaoka K; Saito K; Tanaka Y
Mod Rheumatol; 2015 May; 25(3):344-9. PubMed ID: 25295918
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial.
Brahe CH; Østergaard M; Johansen JS; Defranoux N; Wang X; Bolce R; Sasso EH; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll C; Jørgensen A; Krintel SB; Raun J; Hetland ML
Scand J Rheumatol; 2019 Jan; 48(1):9-16. PubMed ID: 29985080
[TBL] [Abstract][Full Text] [Related]
4. Relationship Between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis.
Wang J; Devenport J; Low JM; Yu D; Hitraya E
Arthritis Care Res (Hoboken); 2016 Jun; 68(6):882-5. PubMed ID: 26473986
[TBL] [Abstract][Full Text] [Related]
5. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
[TBL] [Abstract][Full Text] [Related]
6. Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage.
Krabbe S; Bolce R; Brahe CH; Døhn UM; Ejbjerg BJ; Hetland ML; Sasso EH; Chernoff D; Hansen MS; Knudsen LS; Hansen A; Madsen OR; Hasselquist M; Møller J; Østergaard M
Scand J Rheumatol; 2017 Sep; 46(5):353-358. PubMed ID: 27682742
[TBL] [Abstract][Full Text] [Related]
7. A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.
Hambardzumyan K; Saevarsdottir S; Forslind K; Petersson IF; Wallman JK; Ernestam S; Bolce RJ; van Vollenhoven RF
Arthritis Rheumatol; 2017 May; 69(5):953-963. PubMed ID: 27992691
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab.
Fleischmann R; Connolly SE; Maldonado MA; Schiff M
Arthritis Rheumatol; 2016 Sep; 68(9):2083-9. PubMed ID: 27111089
[TBL] [Abstract][Full Text] [Related]
9. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
Kojima T; Yabe Y; Kaneko A; Hirano Y; Ishikawa H; Hayashi M; Miyake H; Takagi H; Kato T; Terabe K; Wanatabe T; Tsuchiya H; Kida D; Shioura T; Funahashi K; Kato D; Matsubara H; Takahashi N; Hattori Y; Asai N; Ishiguro N
Mod Rheumatol; 2013 Sep; 23(5):977-85. PubMed ID: 23099471
[TBL] [Abstract][Full Text] [Related]
10. Predictive ability, validity, and responsiveness of the multi-biomarker disease activity score in patients with rheumatoid arthritis initiating methotrexate.
Luedders BA; Johnson TM; Sayles H; Thiele GM; Mikuls TR; O'Dell JR; England BR
Semin Arthritis Rheum; 2020 Oct; 50(5):1058-1063. PubMed ID: 32911284
[TBL] [Abstract][Full Text] [Related]
11. Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.
Hirata S; Li W; Kubo S; Fukuyo S; Mizuno Y; Hanami K; Sawamukai N; Yamaoka K; Saito K; Defranoux NA; Tanaka Y
Mod Rheumatol; 2016 Nov; 26(6):850-856. PubMed ID: 26873570
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.
Hambardzumyan K; Bolce R; Saevarsdottir S; Cruickshank SE; Sasso EH; Chernoff D; Forslind K; Petersson IF; Geborek P; van Vollenhoven RF
Ann Rheum Dis; 2015 Jun; 74(6):1102-9. PubMed ID: 24812287
[TBL] [Abstract][Full Text] [Related]
13. A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis.
Ma MHY; Defranoux N; Li W; Sasso EH; Ibrahim F; Scott DL; Cope AP
Arthritis Res Ther; 2020 Jun; 22(1):158. PubMed ID: 32580789
[TBL] [Abstract][Full Text] [Related]
14. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study.
Hirata S; Dirven L; Shen Y; Centola M; Cavet G; Lems WF; Tanaka Y; Huizinga TW; Allaart CF
Rheumatology (Oxford); 2013 Jul; 52(7):1202-7. PubMed ID: 23392591
[TBL] [Abstract][Full Text] [Related]
15. Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis.
Li W; Sasso EH; van der Helm-van Mil AH; Huizinga TW
Rheumatology (Oxford); 2016 Feb; 55(2):357-66. PubMed ID: 26385370
[TBL] [Abstract][Full Text] [Related]
16. Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies.
Curtis JR; Brahe CH; Østergaard M; Lund Hetland M; Hambardzumyan K; Saevarsdottir S; Wang X; Flake Ii DD; Sasso EH; Huizinga TW
Curr Med Res Opin; 2019 Sep; 35(9):1483-1493. PubMed ID: 30777458
[No Abstract] [Full Text] [Related]
17. The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.
Roodenrijs NMT; de Hair MJH; Wheater G; Elshahaly M; Tekstra J; Teng YKO; Lafeber FPJG; Hwang CC; Liu X; Sasso EH; van Laar JM
Arthritis Res Ther; 2018 Nov; 20(1):256. PubMed ID: 30458871
[TBL] [Abstract][Full Text] [Related]
18. Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
Kizaki K; Yamashita F; Hayashi T; Funakoshi N
Int J Rheum Dis; 2018 Oct; 21(10):1815-1821. PubMed ID: 27778459
[TBL] [Abstract][Full Text] [Related]
19. Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia.
Lee YC; Hackett J; Frits M; Iannaccone CK; Shadick NA; Weinblatt ME; Segurado OG; Sasso EH
Rheumatology (Oxford); 2016 Apr; 55(4):640-8. PubMed ID: 26608972
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression.
van der Helm-van Mil AH; Knevel R; Cavet G; Huizinga TW; Haney DJ
Rheumatology (Oxford); 2013 May; 52(5):839-46. PubMed ID: 23287359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
